Effects of Dapagliflozin Adjunct to Insulin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes: A Randomized, Controlled, Open-Labeled Trial

Table 2

Blood glucose variability in the recruited subjects.

Parameter	Before therapy		value	After therapy (5 w)		value
	DAPA+CSII	CSII		DAPA+CSII	CSII
MAGE			0.68			0.03
MBG			0.83			0.10
SD			0.94			0.07
CV%			0.84			0.14
mmol/L	2.05 (1.19, 4.20)	2.48 (0.90, 3.93)	0.89	0 (0, 0)	0.02 (0, 0.40)	0.01
mmol/L	0 (0, 0)	0 (0, 0)	0.33	0 (0, 0)	0 (0, 0)	0.03
Hypoglycemia ()	0	0	/	0	4	0.05
TIR			0.42			0.01

MAGE: the mean amplitude of glycemic excursion; MBG: 24 h mean blood glucose; SD: standard deviation of mean glucose; CV%: the coefficient of variation;  mmol/L: the incremental area under the curve (AUC) of a  mmol/L;  mmol/L: the incremental area over the curve (AOC) of a  mmol/L; TIR: the time in target range (3.9-10.0 mmol/L). Data were presented as or IQR. ; .